tetano
Editor, Senior Moderator
J Virol. 2020 Apr 17. pii: JVI.00510-20. doi: 10.1128/JVI.00510-20. [Epub ahead of print]
Human leukocyte antigen susceptibility map for SARS-CoV-2.
Nguyen A[SUP]1,[/SUP][SUP]2[/SUP], David JK[SUP]1,[/SUP][SUP]2[/SUP], Maden SK[SUP]1,[/SUP][SUP]2[/SUP], Wood MA[SUP]1,[/SUP][SUP]3[/SUP], Weeder BR[SUP]1,[/SUP][SUP]2[/SUP], Nellore A[SUP]4,[/SUP][SUP]2,[/SUP][SUP]5[/SUP], Thompson RF[SUP]4,[/SUP][SUP]2,[/SUP][SUP]6,[/SUP][SUP]7,[/SUP][SUP]8[/SUP].
Author information
Abstract
Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen [lsqb]HLA[rsqb] A, B, and C) may affect susceptibility to and severity of severe acute respiratory syndrome 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We execute a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across 145 HLA -A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explore the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome is successfully sampled and presented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (Lin M, Tseng H-K, Trejaut JA, Lee H-L, Loo J-H, Chu C-C, Chen P-J, Su Y-W, Lim KH, Tsai Z-U, Lin R-Y, Lin R-S, Huang C-H. BMC Med Genet 4:9. 2003.). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting it could enable cross-protective T-cell based immunity. Finally, we report global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.IMPORTANCE Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of viral severity in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination.
Copyright ? 2020 Nguyen et al.
PMID:32303592DOI:10.1128/JVI.00510-20
Human leukocyte antigen susceptibility map for SARS-CoV-2.
Nguyen A[SUP]1,[/SUP][SUP]2[/SUP], David JK[SUP]1,[/SUP][SUP]2[/SUP], Maden SK[SUP]1,[/SUP][SUP]2[/SUP], Wood MA[SUP]1,[/SUP][SUP]3[/SUP], Weeder BR[SUP]1,[/SUP][SUP]2[/SUP], Nellore A[SUP]4,[/SUP][SUP]2,[/SUP][SUP]5[/SUP], Thompson RF[SUP]4,[/SUP][SUP]2,[/SUP][SUP]6,[/SUP][SUP]7,[/SUP][SUP]8[/SUP].
Author information
Abstract
Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen [lsqb]HLA[rsqb] A, B, and C) may affect susceptibility to and severity of severe acute respiratory syndrome 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We execute a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across 145 HLA -A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explore the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome is successfully sampled and presented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (Lin M, Tseng H-K, Trejaut JA, Lee H-L, Loo J-H, Chu C-C, Chen P-J, Su Y-W, Lim KH, Tsai Z-U, Lin R-Y, Lin R-S, Huang C-H. BMC Med Genet 4:9. 2003.). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting it could enable cross-protective T-cell based immunity. Finally, we report global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.IMPORTANCE Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of viral severity in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination.
Copyright ? 2020 Nguyen et al.
PMID:32303592DOI:10.1128/JVI.00510-20